Rocket Pharmaceuticals, Inc. (RCKT) Income Statement
RCKT 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRCKT revenue and net income
RCKT growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RCKT quarterly EPS vs estimates
Rocket Pharmaceuticals beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.39).
RCKT income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $11.0M | $9.4M | $7.1M | $6.3M | $5.4M | $1.1M | $426,000 | $330,000 | $204,000 | $169,000 |
| Gross profit | −$11.0M | −$9.4M | −$7.1M | −$6.3M | −$5.4M | −$1.1M | −$426,000 | −$330,000 | −$204,000 | −$169,000 |
| Research & development | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M | $106.4M | $58.6M | $53.3M | $14.2M | $32.0M |
| Sales, general & admin | $86.5M | $102.0M | $75.0M | $58.8M | $41.8M | $27.9M | $17.5M | $17.9M | $12.5M | $9.9M |
| Total operating expenses | $217.5M | $273.2M | $259.7M | $224.3M | $167.2M | $134.9M | $75.9M | $71.0M | $26.7M | $41.9M |
| Operating income | −$228.5M | −$273.2M | −$259.7M | −$224.3M | −$167.2M | −$136.0M | −$76.2M | −$71.2M | −$26.7M | −$41.9M |
| Interest income | $10.5M | $16.3M | $13.1M | $3.9M | $3.1M | $2.1M | $3.4M | $1.7M | $819,000 | $443,000 |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $5.9M | $7.5M | $4.8M | $5.2M | $3.6M | $1.4M |
| Income before taxes | −$223.1M | −$258.7M | −$245.6M | −$221.9M | −$169.1M | −$139.7M | −$77.3M | −$74.5M | −$29.5M | −$42.9M |
| Income taxes | — | −$1 | −$245.6M | −$2.5M | $516,000 | $7.0M | $6.0M | $2.7M | $819,000 | $443,000 |
| Net income | −$223.1M | −$258.7M | −$245.6M | −$221.9M | −$169.1M | −$146.7M | −$83.2M | −$74.5M | −$29.5M | −$42.9M |
| EBITDA | −$210.2M | −$247.5M | −$236.6M | −$213.7M | −$157.8M | −$131.6M | −$71.1M | −$71.2M | −$20.0M | −$41.3M |
| EPS (diluted) | −$1.98 | −$2.73 | −$2.94 | −$3.26 | −$2.68 | −$2.51 | −$1.58 | −$1.74 | −$3.55 | −$6.40 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $9.2M | $0 | $0 | $0 | $10.3M | $0 |
| Cost of revenue | — | $2.1M | — | — | $2.5M | $3.0M | $4.6M | $2.4M | $2.3M | $2.3M | $5.2M | $1.8M |
| Gross profit | — | −$2.1M | — | — | −$2.5M | −$3.0M | $4.6M | −$2.4M | −$2.3M | −$2.3M | $5.2M | −$1.8M |
| Research & development | $29.5M | $31.5M | $29.3M | $34.1M | $42.7M | $35.9M | $37.4M | $42.3M | $44.8M | $43.8M | $41.7M | $46.8M |
| Sales, general & admin | $17.4M | $17.1M | $14.7M | $18.4M | $25.0M | $28.4M | $25.3M | $27.1M | $27.4M | $22.1M | $21.5M | $18.6M |
| Total operating expenses | $46.9M | $46.4M | $44.0M | $52.2M | $71.1M | $64.4M | $62.7M | $69.4M | $71.4M | $65.1M | $63.3M | $65.4M |
| Operating income | −$46.9M | −$48.5M | −$44.0M | −$52.2M | −$71.1M | −$64.4M | −$62.7M | −$69.4M | −$73.7M | −$67.4M | −$63.3M | −$65.4M |
| Interest income | $1.0M | $1.4M | $1.9M | $2.4M | $2.7M | $3.5M | $2.8M | $3.2M | $4.5M | $5.8M | $4.1M | $4.0M |
| Interest expense | $473,000 | $473,000 | $3.3M | $473,000 | $473,000 | $472,000 | $473,000 | $471,000 | $471,000 | $471,000 | $470,000 | $469,000 |
| Income before taxes | $131.8M | −$47.6M | −$42.5M | −$50.3M | −$68.9M | −$61.3M | −$60.3M | −$66.7M | −$69.6M | −$62.1M | −$59.7M | −$61.9M |
| Income taxes | $8.6M | — | — | — | — | — | — | −$66.7M | — | $1 | $1.6M | −$1.8M |
| Net income | $123.2M | −$47.6M | −$42.5M | −$50.3M | −$68.9M | −$61.3M | −$60.3M | −$66.7M | −$69.6M | −$62.1M | −$59.7M | −$61.9M |
| EBITDA | $134.4M | −$45.0M | −$37.0M | −$46.6M | −$65.9M | −$57.9M | −$57.5M | −$63.9M | −$66.8M | −$59.3M | −$57.3M | −$59.7M |
| EPS (diluted) | −$0.15 | −$0.42 | −$0.38 | −$0.45 | −$0.59 | −$0.56 | −$0.62 | −$0.71 | −$0.74 | −$0.66 | −$0.64 | −$0.75 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | 50.0% | — |
| Operating margin | — | — | — | — | — | — | −682.5% | — | — | — | −613.6% | — |
| Net margin | — | — | — | — | — | — | −656.7% | — | — | — | −578.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RCKT's financial statements (latest annual report filed February 26, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RCKT financial results
Rocket Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $223.1 million. Diluted earnings per share came to −$1.98.
See the RCKT stock overview for the latest quote and news, or the RCKT chart for price history and technical indicators.
RCKT income statement FAQ
Does Rocket Pharmaceuticals have revenue?
Rocket Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Rocket Pharmaceuticals profitable?
No. Rocket Pharmaceuticals reported a net loss of $223.1 million in fiscal 2025.
How much does Rocket Pharmaceuticals spend on research and development?
Rocket Pharmaceuticals spent $142.0 million on research and development in fiscal 2025.
What are Rocket Pharmaceuticals's earnings per share?
Rocket Pharmaceuticals earned $-1.98 per diluted share in fiscal 2025, compared with $-2.73 a year earlier.
When will Rocket Pharmaceuticals report its next earnings?
Rocket Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Rocket Pharmaceuticals's fiscal year end?
Rocket Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 26, 2026.